Trevena (TRVN) and Immunic (IMUX) – beragampengetahuan Financial Blog – Beragampengetahuan

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Immunic (IMUX – Research Report) with bullish sentiments.

Trevena (TRVN)

JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena today and set a price target of $4.00. The company’s shares closed last Tuesday at $0.59, close to its 52-week low of $0.51.

According to beragampengetahuan.com, Butler is ranked 0 out of 5 stars with an average return of -15.0% and a 32.3% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Vigil Neuroscience Inc, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Trevena is a Moderate Buy with an average price target of $4.00.

See the top stocks recommended by analysts >>

Immunic (IMUX)

In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Immunic, with a price target of $7.00. The company’s shares closed last Tuesday at $1.00, close to its 52-week low of $0.95.

According to beragampengetahuan.com, Argyrides ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.7% and a 26.8% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Rani Therapeutics Holdings, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Immunic is a Moderate Buy with an average price target of $13.33.

beragampengetahuan has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TRVN: